Literature DB >> 10617466

Pharmacological rescue of mutant p53 conformation and function.

B A Foster1, H A Coffey, M J Morin, F Rastinejad.   

Abstract

Compounds that stabilize the DNA binding domain of p53 in the active conformation were identified. These small synthetic molecules not only promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation. A prototype compound caused the accumulation of conformationally active p53 in cells with mutant p53, enabling it to activate transcription and to slow tumor growth in mice. With further work aimed at improving potency, this class of compounds may be developed into anticancer drugs of broad utility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10617466     DOI: 10.1126/science.286.5449.2507

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  195 in total

1.  Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.

Authors:  G K Kovvali; B Mehta; C B Epstein; S G Lutzker
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

2.  A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Authors:  Assaf Friedler; Lars O Hansson; Dmitry B Veprintsev; Stefan M V Freund; Thomas M Rippin; Penka V Nikolova; Mark R Proctor; Stefan Rüdiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function.

Authors:  Heather Sadlish; Frederick M R Williams; Wayne F Flintoff
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

4.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

Review 5.  Molecular biology of breast cancer.

Authors:  Miguel Martín
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

6.  Single nucleotide polymorphism seeking long term association with complex disease.

Authors:  Brian W Kirk; Matthew Feinsod; Reyna Favis; Richard M Kliman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

7.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

8.  Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Authors:  Drew D Dudgeon; Sunita N Shinde; Tong Ying Shun; John S Lazo; Christopher J Strock; Kenneth A Giuliano; D Lansing Taylor; Patricia A Johnston; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2010-08       Impact factor: 1.738

Review 9.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

10.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Authors:  Natalia Issaeva; Assaf Friedler; Przemyslaw Bozko; Klas G Wiman; Alan R Fersht; Galina Selivanova
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.